The lens epithelium-derived growth factor (LEDGF/p75) tethers the mixed-lineage leukemia (MLL1) protein complex to chromatin. Likewise, LEDGF/p75 tethers the HIV-1 pre-integration complex to chromatin. We previously demonstrated that expression of the C-terminal fragment fused to enhanced green fluorescent protein (eGFP) (eGFP-LEDGF 325-530 ) impaired HIV-1 replication. Here, we explored this strategy to selectively interfere with the leukemogenic activity of MLL-fusion proteins. We found that expression of LEDGF 325-530 impaired the clonogenic growth of MLL-fusion gene transformed human and mouse hematopoietic cells, without affecting the growth of control cells immortalized by the FLT3-ITD mutant or normal lineage-marker-depleted murine bone marrow cells. Expression of LEDGF 325-530 was associated with downregulation of the MLL target Hoxa9 and impaired cell cycle progression. Structure-function analysis revealed two small eGFP-fused LEDGF/p75 peptides, LEDGF [424][425][426][427][428][429][430][431][432][433][434][435] and LEDGF 375-386 phenocopying these effects. Both LEDGF 325-530 and the smaller active peptides were able to disrupt the LEDGF/p75-MLL interaction. Expression of LEDGF or LEDGF 375-386 fragments increased the latency period to disease development in vivo in a mouse bone marrow transplant model of MLL-AF9-induced AML. We conclude that small peptides disrupting the LEDGF/p75-MLL interface have selective anti-leukemic activity providing a direct rationale for the design of small molecule inhibitors targeting this interaction.
INTRODUCTION
The majority of infant acute leukemia and a significant fraction of childhood and adult acute leukemia have chromosomal translocations involving the mixed-lineage leukemia (MLL1) gene. 1, 2 The translocations t(4;11)(q21;q23), t(9;11) (p22;q23) and t(11;19)(p12;q23), resulting in MLL-AF4, MLL-AF9 and MLL-ENL fusions, cover 460% of the cases. 2 Expression of MLL-fusion genes in hematopoietic stem and progenitor cells impairs normal differentiation and provides aberrant self-renewal capacity. 3 Biochemical studies revealed that, similar to wild-type (WT) MLL, MLL-fusions are part of multi-protein complexes involved in chromatin remodeling and transcriptional regulation that could serve as potential therapeutic targets. 4, 5 Moreover, recent studies have demonstrated that tethering of MLL complexes to chromatin is mediated by several proteins including the lens epitheliumderived growth factor/p75 (LEDGF/p75). [6] [7] [8] [9] LEDGF/p75 was previously identified as a transcriptional coactivator and a component of the general RNA polymerase II transcription machinery. 10 LEDGF/p75 is also an essential cellular co-factor of HIV-1, the causative agent of the AIDS. During HIV-1 replication LEDGF/p75 binds the viral integrase and tethers the pre-integration complex to host chromatin. 11 This function is orchestrated by an ensemble of chromatin binding motifs at the N-terminal end of LEDGF/p75 and the integrase-binding domain (IBD, aa 347-429) at the C-terminus (Figure 1a ). It was shown that via inhibition of the integration step, knockdown or knockout of LEDGF/p75 inhibits HIV replication. [11] [12] [13] [14] In addition, expression of the C-terminal end of LEDGF/p75 (aa 325-530) that lacks the chromatin binding motifs fused to enhanced green fluorescent protein (eGFP) (Figure 1a ), also blocks viral replication. [14] [15] [16] The eGFP-LEDGF 325-530 fragment binds integrase and outcompetes endogenous LEDGF/p75, impeding HIV chromatin tethering. These findings provided a proof-of-principle for a novel antiviral therapeutic strategy targeting the interaction between the viral integrase and its cellular co-factor LEDGF/p75, and resulted in the development of potent small molecules that block HIV-1 replication and are currently in advanced pre-clinical development. 17 Several lines of evidence link LEDGF/p75 to human leukemogenesis. First, a leukemia-associated chromosomal translocation t(9;11)(p22;p15) was found to result in a fusion of the N-terminal part of the nucleopore 98 protein (NUP98) to the C-terminus of LEDGF/p75. 18 Second, elevated LEDGF/p75 expression levels were reported in blasts from chemotherapy-resistant AML patients. 19 Third and most importantly, LEDGF/p75 has been identified as an essential co-factor of the oncogenic functions of the MLL-fusion complexes. By biochemical dissection of the MLL-fusion complex, menin (the protein encoded by MEN1) was found to serve as a molecular adaptor that physically links MLL with LEDGF/p75 through binding of the IBD. Knockdown experiments suggested LEDGF/p75 to be required for MLL-dependent leukemic transformation. 8 The striking analogy between the chromatin-tethering function of LEDGF/p75 in HIV replication and MLL leukemia fueled the hypothesis that blocking the interaction between LEDGF/p75 and MLL/menin might impair the formation of the MLL-fusion complex and leukemic transformation providing a proof-ofprinciple for a novel therapeutic strategy against leukemia. Here, we demonstrate for the first time that, by disrupting the interaction between LEDGF/p75 and the MLL/menin complex, MLL-fusion-mediated transformation can be selectively inhibited both in vitro and in vivo.
MATERIALS AND METHODS

Generation of murine MLL-fusion-expressing AML cells
Murine MLL-fusion-expressing AML cells were generated by transplantation of bone marrow cells stably transduced to express MLL-AF9 or MLL-ENL using a previously published protocol with some modifications. 20 In brief, cells were harvested from 8-weeks-old (FVB/Nx129/S1) F1 mice 4 days after fluorouracil injection (150 mg/kg). Lineage-marker-depleted progenitors (Cell Mag Kit, R&D systems, Minneapolis, MN, USA) were cultured for 24 h in RPMI-1640 (10% FCS, 1% penicillin/streptomycin, 10 ng/ml of human interleukin-6 (IL-6), 6 ng/ml of murine interleukin-3 (IL-3) and 100 ng/ml of murine stem cell factor before transduction with hightiter retrovirus by spinoculation of the cells (2000 g, 90 min at 33 1C) on two consecutive days. In all, 5 Â 10 5 transduced bone marrow cells were injected into the tail vein of lethally irradiated (950 rad) syngenic recipients. As described previously, 100% of the mice developed AML after 60-90 days latency. 20 Cells were harvested from the bone marrow and expanded in medium containing growth factors.
Transduction of murine and human cells
Murine cells were transduced using the protocol described above with pMSCV-IRES-eGFP-LEDGF-fragments, pMSCV-LEDGF-ShRNA-PGK-Puro or pMSCV-IRES-eGFP-PGK-Puro. Cells were flow-sorted for eGFP expression 24 h after the second spinoculation and used as indicated for the different assays.
Human AML cell lines were transduced with concentrated lentiviral supernatants (see Supplementary materials and methods) containing expression vectors pSFFV-eGFP-I-Puro-WS, pSFFV-eGFP-LEDGF-fragments-IPuro-WS and pSFFV-eGFP-I-Puro 2xmi p75 WS. Forty-eight hours posttransduction the eGFP þ cells were flow-sorted for eGFP and/or selected with puromycin as indicated.
Clonogenic growth assays in vitro
Clonogenic growth was determined by plating cells in methylcellulose. MLL-fusion or WT mouse derived cells were plated in murine methylcel lulose containing IL-3, IL-6 and murine stem cell factor (M3534, Stem cell technologies, Vancouver, British Columbia, Canada) in the presence of 2-4 mg/ml puromycin. Ba/F3-FLT3-ITD cells as well as the human AML cell lines were plated in methylcellulose without cytokines (Stem Alpha.mIE, Stem Alpha, St Clement les Places, France) in the presence of 2 mg/ml puromycin. The number of colonies was counted after 5-7 days for murine cells and after 10 days for human cell lines.
Leukemogenesis study in vivo
To address effects on the in vivo leukemogenic potential, 5 Â 10 4 eGFPpositive murine MLL-AF9 þ cells, sorted by FACS, were mixed with 1 Â 10 6 normal bone marrow cells from a healthy donor and transplanted into the tail vain of lethally irradiated syngeneic (FVB/Nx129/S1) F1-recipient mice.
Growth monitoring
In all, 2 Â 10 4 flow-sorted eGFP-positive MLL-AF9 murine transformed cells were plated in medium containing growth factors with 2 mg/ml puromycin. Growth was monitored for 7 days by daily counting of live cells using the Trypan Blue exclusion test (Gibco, Invitrogen, Life Technologies, Paisley, UK).
Cell cycle analysis
Ninety-six hours after transduction cells were fixed in 2% PFA for 10 min at room temperature washed, permeabilized with NET Gel (150 mM NaCl, 5 mM EDTA, 50 mM Tris-HCl pH 7.4, 0.05% NP-40, 0.25% Lambda carrageenan (Sigma-Aldrich, St Louis, MO, USA)) and stained with DAPI Impairing mixed-lineage leukemia through LEDGF/p75 H Mé reau et al (in PBS: 0.1% Triton X-100, 1 mg/ml DAPI (Gibco, Invitrogen)) for 30 min at room temperature. The samples were run on a Cyan ADP Flow Cytometer (Dako Cytomation, Glostrup, Denmark) using Summit software (Summit Software Solutions Inc., Poway, CA, USA). The data were analyzed using Flowjo software (Tree Star Inc., Ashland, OR, USA).
Reverse transcription quantitative-PCR
RNA was extracted using TRIZOL reagent (Life technologies, Grand Island, NY, USA) according to the manufacturer's protocol. cDNA synthesis was carried out with the high capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA). The Hoxa9 mRNA expression level was assessed in duplicate by quantitative real-time PCR using SyBR Green on an ABI prism 7700 Sequence Detection System (Applied Biosystems). Results were calibrated with Gapdh and calculated as DDCT values normalized to vector control. The primer pairs used are described in Supplementary  Table 1 . Quantitative-PCR analysis of LEDGF/p75 RNA levels in THP1 cells was performed as previously described. 21 
Statistical analysis
Mean values and s.d. were calculated to estimate the degree of variation and GraphPad Prism 5.0 software (Pnsm Software Corp., Irvine, CA, USA) was used for statistical analysis, as specified for each experiment in the figure legends. Information about used cell lines, plasmids as well as experimental procedures for co-immunoprecipitation (co-IP), protein extraction and AlphaScreen are described in a Supplementary data file.
RESULTS
Expression of eGFP-LEDGF 325-530 selectively impairs clonogenic growth of murine and human MLL-fusion-expressing leukemic cells As expression of eGFP-LEDGF 325-530 containing the IBD ( Figure 1a ) was able to impair HIV-1 replication through competition with endogenous LEDGF/p75, we questioned whether this fragment also affects the growth of MLL-fusion-transformed hematopoietic cells. 15 To this purpose we used leukemic blasts derived from murine AML, induced by transplanting bone marrow cells expressing the MLL-AF9 or MLL-ENL fusion. As a control, normal mouse bone marrow (WT BM) and the murine Ba/F3 cell line rendered IL-3 independent by expression of the FLT3-ITD mutation (Ba/F3-FLT3/ITD) were used. 22 Cells were transduced with a stem cell virus based retroviral vector (pMSCV) expressing eGFP-LEDGF 325-530 . MSCV vectors expressing eGFP and eGFP together with a LEDGF/p75 specific short hairpin to induce LEDGF knockdown (LEDGF KD), were used respectively as negative and positive control. Forty-eight hours post-transduction, eGFP þ cells were flow-sorted and seeded in methylcellulose. As shown in Figure 1b expression of eGFP-LEDGF 325-530 significantly reduced the number of MLL-AF9 (77%) or MLL-ENL (56%) expressing murine AML colonies, comparable to the effect of LEDGF/p75 knockdown (respectively, 68% and 40%). 8 This phenotype was maintained over two rounds of consecutive plating in MLL-AF9 expressing cells (Supplementary Figure S1) . In contrast, the colony growth of WT bone marrow enriched for stem and progenitor cells by depletion of lineage marker-expressing cells, or Ba/F3-FLT3/ITD cells was not significantly affected ( Figure 1b) . Q-PCR analysis indicated that expression of LEDGF 325-530 was associated with a significant reduction of Hoxa9 mRNA levels, a known MLL-fusion target, in MLL-AF9 (47%) and MLL-ENL (34%) fusion-transformed cells (Figure 1c) . 23 These results were corroborated in human cells. We expressed eGFP-LEDGF 325-530 or the respective controls using a lentiviral vector in MLL-AF9 þ THP1 and MOLM13 leukemia cell lines that form colonies in semi-solid medium. HL60 cells (MLL WT) served as control. 24 Expression in THP1 cells was confirmed by western blot and knockdown of LEDGF/p75 was verified by Q-PCR (Supplementary Figure S2) . As expected, compared with eGFP, eGFP-LEDGF 325-530 significantly impaired the clonogenic growth The capacity of LEDGF 325-530 to displace LEDGF/p75 was confirmed in vitro using an AlphaScreen approach with purified recombinant proteins. Next to full-length His-Thioredoxin-menin (H-Trx-menin) and Flag-LEDGF/p75, the N-terminal part of MLL containing the first 160 amino acids fused to Glutathione Impairing mixed-lineage leukemia through LEDGF/p75 H Mé reau et al S-Transferase (MLL 1-160 -GST) was purified (Supplementary Figure  S3A) . As predicted from the available structural information and as shown before, MLL interacted with menin in the absence of LEDGF/p75 (apparent K d ¼ 50.9±9.6 nM), whereas the MLL 1-160 -GST F9A substitution largely abolished this interaction (Supplementary Figure S3B) . 8 Moreover, in this assay we corroborated the inhibitory effects of two recently reported compounds on the MLL-menin interaction CIM056311, IC 50 77.2 nM (95% CI (28.6; 82.0)) and CIM056281, IC 50 109.7 nM (95% CI (92.9; 129.6)), underscoring the specificity of our assay (Supplementary Figure S3C) . 25 We also analyzed the interaction between Flag-LEDGF/p75 and MLL 1-160 -GST (apparent K d ¼ 3,1 ± 0.3 nM). To further confirm the specificity of this interaction we introduced F129A, R130A and E135Q mutations in MLL, based on the available structural information. 26 As expected, these mutations abrogated the interaction with LEDGF/p75 (Supplementary Figure S3D ). An interaction between Flag-LEDGF/p75 and menin could not be detected suggesting that MLL is required as a third partner to form the LEDGF/p75 binding pocket (Supplementary Figure S3D) . 26 To analyze whether LEDGF 325-530 competes with LEDGF/p75 for MLL binding, increasing amounts of MBP-LEDGF 325-530 were added to the MLL 1-160 -GST/ Flag-LEDGF/p75 AlphaScreen assay. As shown in Figure 4b , we observed a significantly (P ¼ 0.0169 log-rank test) increased latency period to disease development in the eGFP-LEDGF 325-530 expressing group (78-96 days, median 88.5 days) compared with the eGFP control group (48-78 days; median 55 days). All animals ultimately succumbed to AML characterized by elevated white blood counts, hepatosplenomegaly and multiorgan infiltration (data not shown).
LEDGF/p75-derived peptides impair clonogenic growth of murine and human MLL-fusion expressing leukemic cells In a first step towards the development of small molecules that can mimic the LEDGF 325-530 phenotype we aimed to identify a minimal domain of LEDGF 325-530 sufficient to impair the clonogenic activity of MLL-fusion-expressing leukemic cells. We screened a set of C-and N-terminal truncation mutants of LEDGF 325-530 for their effect on the clonogenic activity of MLL-AF9 murine leukemic blasts (Supplementary Figures S4A and B) . Similar to eGFP-LEDGF 325-530 , both eGFP-fused C-terminal truncations (LEDGF 325-409 , and LEDGF 325-386 ) retained their negative effect on colony formation (55% and 30% compared with eGFP, respectively). From the N-terminal deletions only LEDGF 424-530 retained its activity (18% compared with eGFP). This result suggests that two regions of LEDGF/p75 are involved in tethering the MLL complex to its target loci on the genome; 325-386aa (located at the very N-terminal part of the IBD) and 424-449aa (just C-terminal from the IBD). Starting from these two regions additional deletion mutants were generated and introduced in MLL-fusion cells (Supplementary Figures S4A and B) , which resulted in the identification of two eGFP-fused peptide-sized fragments, LEDGF 424-435 and LEDGF [375] [376] [377] [378] [379] [380] [381] [382] [383] [384] [385] [386] , that impaired the clonogenic growth of murine MLL-AF9. Expression of eGFP-fused LEDGF 424-530 and LEDGF 325-386 and of the two peptide-sized fragments, LEDGF 424-435 and LEDGF 375-386 , was analyzed by western blot in BAF3 FLT3-ITD cells (Supplementary Figure S5) and their activity on clonogenic growth was validated in MLL-AF9 and MLL-ENL murine AML blasts in vitro with a decrease of at least 40% (Figure 5a ). Both fragments also significantly reduced expression of Hoxa9 in MLL-AF9 (Po0.005, one-way analysis of variance compared with eGFP) and MLL-ENL þ (Po0.001, oneway analysis of variance compared with eGFP) transformed hematopoietic cells (Figure 5b ). In addition, expression of LEDGF 424-435 and LEDGF 375-386 fragments impaired the growth of MLL-AF9 þ cells in liquid culture by 3-4 fold (Figure 5c ) and similar to LEDGF 325-530 , their expression was associated with altered cellular and nuclear morphology of murine MLL-AF9 cells (Supplementary Figure S7A) . The effect of the peptide-sized fragments on cell proliferation was confirmed in human cells. As observed for eGFP-LEDGF 325-530 , expression of eGFP-LEDGF [424] [425] [426] [427] [428] [429] [430] [431] [432] [433] [434] [435] and eGFP-LEDGF 375-386 in MLL-AF9 þ THP1 and MOLM13 cells reduced clonogenic growth of at least 40% opposed to the MLL WT HL60 cells (Figure 6a) . Expression of LEDGF 424-435 and LEDGF 375-386 fragments also impaired the growth of human MV4;11 MLL-AF4 þ cells by 2-3 fold in liquid culture, while non-MLL transformed acute leukemia cell lines, Jurkat (T-ALL), Kasumi (AML1-ETO þ AML) and HL60 (AML) were slightly or not affected (Supplementary Figure S6) . In addition, expression eGFP-LEDGF 424-435 and eGFP-LEDGF 375-386 also resulted in diminished cell cycle progression (Figure 6b) . However, expression of LEDGFfragments did not result in increased apoptosis or terminal differentiation in murine or human MLL-fusion þ leukemic cells (Supplementary Figure S7B and data not shown) . Taken together, these data show that expression of two small LEDGF/p75-derived peptides can impair the clonogenic growth of murine and human MLL-fusion-expressing leukemic cells. Figure S4A) . Both proteins inhibited the direct interaction between MLL and LEDGF/p75 in an AlphaScreen assay with IC 50 values of 48.0 (95% CI (39.3; 58.6)) and 52.4 nM (95% CI (43.9; 63.9)), respectively, while an unrelated control peptide was unable to disrupt the complex (Figure 7a ). In the same assay we also tested the activity of untagged peptides. Although the untagged LEDGF 424-435 peptide did not block the MLL-LEDGF/p75 interaction, LEDGF 375-386 clearly abrogated the interaction with an IC 50 of 7.0 mM (95% CI (3.6; 9.2)) (Figure 7b ).
Expression of LEDGF 375-386 impairs MLL-AF9 acute leukemia in vivo Finally, the effect of the eGFP-fused LEDGF 375-386 peptide was validated in vivo in the bone marrow transplantation mouse model described before (Figure 4a) . Expression of eGFP-LEDGF 375-386 resulted in a moderately prolonged latency of the (Figure 7c ). All animals ultimately succumbed to AML characterized by elevated white blood counts, hepatosplenomegaly and multi-organ infiltration (data not shown).
DISCUSSION LEDGF/p75 has been proposed as an important co-factor of MLL acute leukemia through tethering of the MLL-fusion protein complexes to chromatin. 8 Likewise, LEDGF/p75 is a key host-cell co-factor during HIV-1 replication as it tethers the viral pre-integration complex to active transcription units. 11 Expression of an eGFP-fused LEDGF/p75 C-terminal fragment (eGFP-LEDGF 325-530 ) containing the IBD including the MLL/menin interaction domain, was able to selectively impair HIV-1 replication through competition with endogenous LEDGF/p75. [14] [15] [16] Here, we explored whether this strategy could impede MLL-fusionmediated leukemogenesis. First, we showed that expression of eGFP-LEDGF 325-530 significantly impaired clonogenic growth of murine MLL-AF9 or MLL-ENL transformed cells, as well as MLL-AF9-transformed human leukemia cell lines. In contrast, expression of eGFP-LEDGF 325-530 did not significantly affect FLT3-ITDtransformed Ba/F3 cells or normal lineage marker-depleted murine bone marrow cells underscoring the specificity of the phenotype (Figures 1 and 2) . Expression of eGFP-LEDGF 325-530 resulted in a growth defect associated with downregulation of Hoxa9, a well-known primary MLL-fusion target. 23 Previous studies demonstrated that small molecule DOT1L, BRD4 or MLL/menin inhibitors led to increased differentiation and apoptosis of MLLfusion-expressing leukemic cells. 25, 29, 30, 35 In contrast we did not observed significant apoptosis or differentiation upon expression of the LEDGF fragments (Supplementary Figure S7B and data not shown). Whether this discrepancy is based on limited expression levels or stability of the interfering LEDGF-fragments needs to be explored.
LEDGF 325-530 disrupted the MLL/menin-LEDGF/p75 complex in co-IP experiments and the AlphaScreen protein-protein interaction assays. Together with the fact that healthy or non-MLL-fusiontransformed cells are not affected by LEDGF 325-530 , these results are in agreement with the hypothesis that LEDGF 325-530 competes with endogenous LEDGF/p75 (Figure 3) . Structure-function analysis aided in the selection of two peptide-sized fragments, LEDGF 424-435 and LEDGF [375] [376] [377] [378] [379] [380] [381] [382] [383] [384] [385] [386] , that phenocopied the effects of LEDGF 325-530 in cell culture (Figures 5 and 6 ). Importantly, like LEDGF 325-530 , the tagged peptide fragments disrupted the LEDGF/ p75-MLL complex in a dose-dependent manner (Figure 7) . Surprisingly, the untagged LEDGF 375-386 peptide inhibited the MLL-LEDGF/p75 interaction, whereas the LEDGF 424-435 peptide did not. Possibly, steric hindrance of the tag helps LEDGF 424-435 to disrupt the complex.
LEDGF [375] [376] [377] [378] [379] [380] [381] [382] [383] [384] [385] [386] and LEDGF [424] [425] [426] [427] [428] [429] [430] [431] [432] [433] [434] [435] are located on either side of the IBD alluding to the existence of two distinct interaction sites on LEDGF/p75. 27 Based on the recently published partial structure of the MLL/menin-LEDGF/p75 complex the LEDGF 424-435 peptide directly targets a critical interface between the aE helix of the LEDGF/p75 IBD, a4 of menin and a2 of MLL, explaining its inhibitory effect (Supplementary Figure S8) . 26 The contacts of the LEDGF 375-386 peptide with the MLL/menin complex were, however, not resolved in the published crystal structure.
We confirmed the direct interaction between recombinant menin and MLL in an AlphaScreen assay. An interaction between recombinant LEDGF/p75 and menin was not observed in the absence of MLL, even though different C and N-terminal tags were tested (Supplementary Figure S3D and data not shown). However, we observed for the first time a direct interaction between MLL and LEDGF/p75 in vitro in the absence of menin (Supplementary Figure S3D) . This is at odds with the co-IP data presented in this manuscript and in previous work that suggested menin to be required for the interaction. 8 It is possible, however, that co-IP experiments might be not sensitive enough to detect the interaction or that the interaction is modulated by posttranslational modifications.
Biochemical characterization of the MLL-fusion complexes initiated the search for therapeutic strategies that either target essential enzymatic co-factors or critical protein-protein interactions. 8 Small molecules that block the activity of co-factors recruited by MLL-fusions, such as DOT1L histone methyltransferase and the bromodomain containing BET family protein, BRD4, have been generated and were shown to impair 
